Navigation Links
VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year'
Date:12/1/2008

DR. RALPH WEISSLEDER HONORED FOR CAREER OF SCIENTIFIC DISCOVERY IN MOLECULAR IMAGING

BEDFORD, Mass., Dec. 1 /PRNewswire/ -- The Radiologic Society of North America (RSNA) honored Ralph Weissleder, MD, PhD, with its "Outstanding Researcher of The Year" Award, recognition afforded annually to one scientist who has made original significant contributions to the field of radiology throughout a career of research. Dr. Weissleder is Professor at Harvard Medical School, as well as Director of both the Center for Systems Biology and the Center for Molecular Imaging Research at Massachusetts General Hospital (MGH).

"The RSNA 'Outstanding Researcher of the Year' award is an important acknowledgement of Dr. Weissleder's vision for molecular imaging as an integral component in the future of clinical medicine," said Kirtland Poss, CEO of VisEn Medical. "Dr. Weissleder's contributions have already benefited basic research and pharmaceutical development across numerous disease states, and these are increasingly advancing the era of personalized- and improved-medicine."

According to the RSNA, each "Outstanding Researcher of the Year" honoree has demonstrated a long-term commitment to radiologic research, including service as a principal investigator on peer-reviewed, nationally funded research programs, mentoring a new generation of research physicians, and leading significant scientific discoveries.

Dr. Weissleder has published over 500 peer-reviewed articles and is a founding member and past President of the Society for Molecular Imaging Research. He is the recipient of numerous scientific awards including the Allyn Taylor Prize in International Medicine, an SMI Lifetime Achievement Award and the Millennium Innovator in Medicine award.

Dr. Weissleder is also known for his significant contributions to molecular imaging research. Most of his work has been aimed at cancer, atherosclerosis and inflammatory diseases and has led to new approaches in the management of these diseases.

Dr. Weissleder is a co-founder of VisEn Medical, which has further developed and commercialized some of the leading fluorescence molecular imaging technologies originating out of Dr. Weissleder's lab at MGH, including "FMT" or fluorescent molecular tomography, as well as a portfolio of fluorescence in vivo imaging agents. The VisEn FMT 2500(TM) quantitative tomography system provides 3D quantification of disease biologies in vivo and is used by leading research institutions and pharma companies worldwide both in research and in drug development. In addition, VisEn develops and markets a broad range of fluorescent in vivo imaging agents enabling the quantification and measurement of key disease-associated biomarkers and therapeutic responses in vivo. These agents are used preclinically today, and along with the Fox Chase Cancer Center, VisEn's first "smart" fluorescence activatable agent is being planned for clinical trials in late 2009 to enable physicians to identify and characterize early stage disease in pancreatic and ovarian cancer patients.

Information on Dr. Weissleder and his work at the MGH can be found on: csb.mgh.harvard.edu and cmir.mgh.harvard.edu

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMT) Imaging Systems provide the industry's most robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific preclinical and clinical research areas.

Additional information can be found at www.visenmedical.com.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
2. VisEn Medical Raises $5.0 Million in Expanded Series B Financing
3. GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
4. Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation
5. Statement by Steve Case, Co-Founder, AOL and Chairman of Accelerate Brain Cancer Cure (www.ABC2.org) on News of Senator Ted Kennedys Brain Cancer Diagnosis
6. The Chopra Center Co-founders Bring Mind-Body Healing to New York City
7. The Chopra Center Co-founders Will Teach a Beginning Course in Meditation and Mind-body Healing This August in Chicago
8. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
9. Allscripts Named to FORTUNE 100 Fastest-Growing Companies List
10. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
11. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: